Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2019-07-24 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 125.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the quarter ended 30 June 2019. It includes operating, investing, and financing cash flows, reconciliation of cash and cash equivalents, payments to directors, and estimated cash outflows for the next quarter. The document is about 15,000 characters long, indicating it is a substantive financial report rather than a brief announcement. The content aligns with a quarterly financial report providing comprehensive financial data for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2019
2019-07-24 English
Quarterly Shareholder Update - June 2019 11 pages 397.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – June 2019' and contains detailed discussion of the company's pipeline progress, clinical trials, regulatory updates, milestone payments, and sales figures for the quarter ending June 2019. It includes substantive financial data such as sales figures for Bronchitol and milestone payments, as well as detailed operational and clinical development updates. The document is approximately 15,000 characters long, indicating it is a comprehensive report rather than a brief announcement. The content aligns with a comprehensive financial and operational report for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. There is no indication that this is an earnings release (which would be more summary and highlight-focused), nor is it an annual report or audit report. It is not a presentation, call transcript, or regulatory filing. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q4 2019
2019-07-24 English
Pathway to US Bronchitol Approval Clarified in FDA Response 2 pages 106.8KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 20 June 2019 from Pharmaxis Ltd announcing that their US licensee Chiesi Group received a complete response letter from the FDA regarding the approval process for Bronchitol for adult cystic fibrosis patients. The release discusses regulatory updates, expected timelines for NDA completion, and commercial arrangements. It is a public announcement about regulatory progress and future expectations, not a detailed financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document is a regulatory update or announcement related to product approval status. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-06-19 English
Change in substantial holding 5 pages 383.3KB
Regulatory Filings
2019-05-29 English
US Advisory Committee Positive Recommendation on Bronchitol 2 pages 138.9KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 9 May 2019 announcing a positive recommendation from a US FDA advisory committee regarding the use of a pharmaceutical product (Bronchitol) for adult cystic fibrosis patients. It discusses regulatory progress, expected FDA decisions, and commercial implications. The content is an announcement of regulatory and commercial updates rather than a detailed financial report, earnings release, or management discussion. It does not contain financial statements, detailed financial data, or comprehensive management analysis. It is not a report of voting results, board changes, or legal proceedings. The document is a public announcement about regulatory and commercial developments, fitting best into the category of Regulatory Filings (RNS) as a general regulatory announcement and update that does not fit more specifically into other categories.
2019-05-08 English
Appendix 4C - quarterly 5 pages 127.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the quarter ended 31 March 2019. It includes operating, investing, and financing cash flows, reconciliation of cash and cash equivalents, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The document is about 8400 characters long, which is substantive and contains actual financial data for a quarterly period. The presence of detailed financial statements and analysis for a quarter aligns with the definition of an Interim / Quarterly Report (IR). It is not a mere announcement or certification, nor is it a full annual report or earnings release. Therefore, the correct classification is IR (Interim / Quarterly Report). Q3 2019
2019-04-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.